Regulated information
Bone Therapeutics strengthens Board with the appointment of Jean
Stéphenne as Chairman
Jean Stéphenne brings
extensive biotech and pharma experience
Gosselies,
Belgium, 20 February 2018, 6 pm CET - BONE THERAPEUTICS
(Euronext Brussels and Paris: BOTHE), the bone cell therapy company
addressing high unmet medical needs in orthopaedics and bone
diseases, today announces that Jean Stéphenne has been appointed
Chairman of the Board of Directors with immediate effect, replacing
Steve Swinson who has informed the Board of his intention to step
down.
Jean Stéphenne is a
highly-experienced life sciences executive, who has served in
senior leadership roles at a large number of biotechnology and
pharmaceutical companies, most recently as Chairman of TiGenix.
Together with the Board of TiGenix, he oversaw the clinical
development and market approval of its most advanced allogeneic
cell therapy product for the treatment of complex perianal fistulas
in Crohn's disease, resulting in Takeda's announced intention to
acquire the company for EUR 520 million.
Jean Stéphenne was also previously
a Member of the Corporate Executive Team of GlaxoSmithKline (GSK)
and Chief Executive of GSK Biologicals (now GSK Vaccines). During
his 40-year tenure, he grew a company of 50 people into a fully
integrated worldwide leader in vaccine development, with 12,000
employees.
Jean Stéphenne currently serves on
the Board of various life sciences companies including TiGenix,
Vaxxilon, OncoDNA, CureVac and Bepharbel. Previous board positions
include Besix Group, BNP Paribas Fortis, GBL and IBA. For his
contribution to the Belgian economy and global public health, he
has received diverse business recognitions and was honoured with
various titles by the Belgian and British governments.
Thomas Lienard,
Chief Executive Officer of Bone Therapeutics, commented:
"We are delighted to welcome Jean Stéphenne as our
new Chairman of the Board. Jean Stéphenne has unparalleled
experience in drug development and building innovative life science
companies and is highly regarded within the sector. We are pleased
to have attracted a Chairman of such calibre, a testament to the
potential of our unique bone cell therapy platform. Jean Stéphenne
will be a valuable addition to an already strong Board, as we
advance our allogeneic cell therapy platform through critical
clinical studies and towards commercialization. I would also like
to express my thanks, on behalf of the Board and leadership team,
to Steve Swinson, who has provided valuable strategic counsel
during his time with the Company."
Jean Stéphenne,
Chairman of Bone Therapeutics commented: "Bone
Therapeutics is a highly innovative Company at the forefront of
developments in bone cell therapy and I am very excited to be
joining the Board. I look forward to working closely with Thomas,
the rest of the Board and the whole Bone Therapeutics team as we
move towards important value inflection points for the Company's
bone cell therapy products for the benefit of patients."
About Bone
Therapeutics
Bone Therapeutics is a leading
cell therapy company addressing high unmet needs in orthopaedics
and bone diseases. Based in Gosselies, Belgium, the Company has a
broad, diversified portfolio of bone cell therapy products in
clinical development across a number of disease areas targeting
markets with large unmet medical needs and limited innovation.
Our technology is based on a
unique, proprietary approach to bone regeneration which turns
undifferentiated stem cells into "osteoblastic", or bone-forming
cells. These cells can be administered via a minimally invasive
procedure, avoiding the need for invasive surgery.
Our primary clinical focus is
ALLOB®, an
allogeneic "off-the-shelf" cell therapy product derived from stem
cells of healthy donors, which is in Phase II studies for the
treatment of delayed-union fractures and spinal fusion. The Company
also has an autologous bone cell therapy product, PREOB®, obtained
from patient`s own bone marrow and currently in Phase III
development for osteonecrosis of the hip, and is also partnered
with Asahi Kasei Corporation for the development and
commercialisation of PREOB® in Japan.
Bone Therapeutics` cell therapy
products are manufactured to the highest GMP standards and are
protected by a rich IP estate covering nine patent families.
Further information is available at: www.bonetherapeutics.com.
Contacts
Bone Therapeutics SA
Thomas Lienard, Chief Executive Officer
Jean-Luc Vandebroek, Chief Financial Officer
Tel: +32 (0)2 529 59 90
investorrelations@bonetherapeutics.com
For Belgium and International
Media Enquiries:
Consilium Strategic
Communications
Amber Fennell, Jessica Hodgson, Hendrik Thys and Lindsey
Neville
Tel: +44 (0) 20 3709 5701
bonetherapeutics@consilium-comms.com
For French Media and Investor
Enquiries:
NewCap Investor Relations &
Financial Communications
Pierre Laurent, Louis-Victor Delouvrier and Nicolas
Merigeau
Tel: + 33 (0)1 44 71 94 94
bone@newcap.eu
For US Media and Investor
Enquiries
Westwicke
Partners
John Woolford
Tel: + 1 443 213 0506
john.woolford@westwicke.com
Certain statements, beliefs and
opinions in this press release are forward-looking, which reflect
the Company or, as appropriate, the Company directors` current
expectations and projections about future events. By their nature,
forward-looking statements involve a number of risks, uncertainties
and assumptions that could cause actual results or events to differ
materially from those expressed or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. A multitude of factors including, but not
limited to, changes in demand, competition and technology, can
cause actual events, performance or results to differ significantly
from any anticipated development. Forward looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, the Company
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or any change in
events, conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither the Company nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person`s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Bone Therapeutics SA via Globenewswire